Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

Exclusion Criteria

• •Concurrent disease in the study eye or structural damage, other than wet AMD, that could compromise BCVA, prevent BCVA improvement, require medical or surgical intervention during the study period, confound interpretation of the results, or interfere with assessment of toxicity or CFP in the study eye.
• •Any ocular/intraocular/periocular infection or inflammation in either eye in the past 12 weeks prior to screening
• •Subretinal hemorrhage with bleeding area of 4 or greater disc area in the study eye
• •History of vitreous hemorrhage in the study eye within 2 months prior to Screening
• •Any condition, including laboratory findings and findings in the medical history or in the pre-study assessments, that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation or prevent the patient from fully participating in all aspects of the study
• •Significant media opacities, including cataract, which might interfere with VA, assessment of toxicity, or fundus imaging